High Court Further Limits Generic-Drug Suits

"An ideologically divided U.S. Supreme Court on Monday further limited the rights of consumers to bring product-liability lawsuits against generic-drug makers.

The court, in a 5-4 ruling, overturned a $21 million judgment won by a New Hampshire woman. She suffered severe injuries allegedly caused by a generic anti-inflammatory drug, sulindac, manufactured by Mutual Pharmaceutical Co., which is owned by a unit of India-based Sun Pharmaceutical Industries Ltd."

To read the full text of this article (subscription required) please click here.